Debio Recherche Pharmaceutique S.A.
Debio Recherche Pharmaceutique S.A., commonly known as Debiopharm, is a prominent biopharmaceutical company headquartered in Switzerland (CH). Founded in 1971, Debiopharm has established itself as a leader in the development of innovative therapies for oncology and infectious diseases, focusing on both drug development and the commercialisation of novel treatments. With a strong presence in Europe and North America, Debiopharm is renowned for its commitment to advancing healthcare through cutting-edge research and development. The company’s core products include targeted therapies and companion diagnostics, which are distinguished by their precision and efficacy. Debiopharm's notable achievements include successful partnerships and collaborations that have propelled its market position, making it a key player in the biopharmaceutical industry. Through its dedication to improving patient outcomes, Debiopharm continues to shape the future of medicine.
DitchCarbon Score
How does Debio Recherche Pharmaceutique S.A.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Debio Recherche Pharmaceutique S.A.'s score of 26 is lower than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Debio Recherche Pharmaceutique S.A.'s reported carbon emissions
Debio Recherche Pharmaceutique S.A., headquartered in Switzerland (CH), currently does not have available data on its carbon emissions, as no specific emissions figures have been provided. Consequently, there are no reported Scope 1, 2, or 3 emissions data to analyse. In the absence of concrete emissions data, it is important to note that the company has not outlined any specific reduction targets or climate commitments. This lack of information suggests that Debio Recherche Pharmaceutique S.A. may still be in the early stages of developing a comprehensive climate strategy or reporting framework. As the pharmaceutical industry increasingly prioritises sustainability and carbon neutrality, it will be essential for Debio to establish clear climate commitments and reduction initiatives to align with industry standards and expectations.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Debio Recherche Pharmaceutique S.A. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
